Adaptation of Stenotrophomonas maltophilia in cystic fibrosis: Molecular diversity, mutation frequency and antibiotic resistance

International Journal of Medical Microbiology

Volumn 304, Issue 5-6, 2014, Pages 613-619

  Vidigal, P G ^a   Dittmer, S ^a   Steinmann, E ^b   Buer, J ^a   Rath, P M ^a   Steinmann, J ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

Author keywords

Antibiotic resistance; Cystic fibrosis; Mutation frequency; Rep PCR; Stenotrophomonas maltophilia

Indexed keywords

ANTIBIOTIC AGENT; CEFTAZIDIME; COLISTIN; COTRIMOXAZOLE; FOSFOMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; MUTAGENIC AGENT; PROTEIN MUTL; PROTEIN MUTS; TIGECYCLINE; TOBRAMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CHILD; CLINICAL ARTICLE; CYSTIC FIBROSIS; DNA FINGERPRINTING; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MISMATCH REPAIR; MUTATION RATE; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; SCHOOL CHILD; SPUTUM SMEAR; STENOTROPHOMONAS MALTOPHILIA; YOUNG ADULT; ADAPTATION; GENETICS; GERMANY; GRAM NEGATIVE INFECTION; MICROBIOLOGY; PHYSIOLOGY; SPUTUM;

ADAPTATION, BIOLOGICAL; ADOLESCENT; ADULT; AGED; CHILD; CYSTIC FIBROSIS; DNA FINGERPRINTING; DRUG RESISTANCE, BACTERIAL; FEMALE; GENETIC VARIATION; GENOTYPE; GERMANY; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; MUTATION RATE; SPUTUM; STENOTROPHOMONAS MALTOPHILIA; YOUNG ADULT;

EID: 84903817534     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2014.04.002     Document Type: Article

References (33)

1. Brooke J.S. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin. Microbiol. Rev. 2012, 25:2-41.
2. Chopra I., O'Neill A.J., Miller K. The role of mutators in the emergence of antibiotic-resistant bacteria. Drug Resist. Updat. 2003, 6:137-145.
3. Ciofu O., Riis B., Pressler T., Poulsen H.E., Høiby N. Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Antimicrob. Agents Chemother. 2005, 49:2276-2282.
4. Clinical and Laboratory Standards Institute Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard - Eighth Edition. CLSI document M07-A8 2009, Clinical and Laboratory Standards Institute, Wayne, PA, USA.
5. Denton M., Tood N.J., Kerr K.G., Hawkey P.M., Littlewood J.M. Molecular epidemiology of Stenotrophomonas maltophilia isolated from clinical specimens from patients with cystic fibrosis and associated environmental samples. J. Clin. Microbiol. 1998, 36:1953-1958.
6. Döring G., Flume P., Heijerman H., Elborn J.S., Consensus Study Group Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J. Cyst. Fibros. 2012, 11:461-479.
7. Ferroni A., Guillemot D., Moumile K., Bernede C., Le Bourgeois M., et al. Effect of mutator P. aeruginosa on antibiotic resistance acquisition and respiratory function in cystic fibrosis. Pediatr. Pulmonol. 2009, 44:820-825.
8. Fluit A.C., Terlingen A.M., Andriessen L., Ikawaty R., van Mansfeld R., et al. Evaluation of the DiversiLab system for detection of hospital outbreaks of infections by different bacterial species. J. Clin. Microbiol. 2010, 48:3979-3989.
9. García-Castillo M., Máiz L., Morosini M.I., Rodríguez-Baños M., Suarez L., et al. Emergence of a mutL mutation causing multilocus sequence typing-pulsed-field gel electrophoresis discrepancy among Pseudomonas aeruginosa isolates from a cystic fibrosis patient. J. Clin. Microbiol. 2012, 50:1777-1778.
10. Giraud A., Matic I., Tenaillon O., Clara A., Radman M., et al. Costs and benefits of high mutation rates: adaptive evolution of bacteria in the mouse gut. Science 2001, 291:2606-2608.
11. Gonçalves Vidigal P., Schmidt D., Stehling F., Mellies U., Steinmann E., et al. Development of a quantitative immunofluorescence assay for detection of Stenotrophomonas maltophilia antibodies in patients with cystic fibrosis. J. Cyst. Fibros. 2013, 12:651-654.
12. Goncalves Vidigal P., Grosse-Onnebrink J., Mellies U., Buer J., Rath P.M., et al. Stenotrophomonas maltophilia in cystic fibrosis: improved detection by the use of selective agar and evaluation of antimicrobial resistance. J. Cyst. Fibros. 2011, 10:422-427.
13. Goss C.H., Mayer-Hamblett N., Aitken M.L., Rubenfeld G.D., Ramsey B.W. Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. Thorax 2004, 59:914-915.
14. Hauser A.R., Jain M., Bar-Meir M., McColley S.A. Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin. Microbiol. Rev. 2011, 24:29-70.
15. Henrichfreise B., Wiegand I., Pfister W., Wiedemann B. Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation. Antimicrob. Agents Chemother. 2007, 51:4062-4070.
16. Hogardt M., Heesemann J. Adaptation of Pseudomonas aeruginosa during persistence in the cystic fibrosis lung. Int. J. Med. Microbiol. 2010, 300:557-562.
17. Maciá M.D., Blanquer D., Togores B., Sauleda J., Pérez J.L., et al. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob. Agents Chemother. 2005, 49:3382-3386.
18. Oliver A., Mena A. Bacterial hypermutation in cystic fibrosis, not only for antibiotic resistance. Clin. Microbiol. Infect. 2010, 16:798-808.
19. Oliver A. Mutators in cystic fibrosis chronic lung infection: prevalence, mechanisms, and consequences for antimicrobial therapy. Int. J. Med. Microbiol. 2010, 300:563-572.
20. Oliver A1, Baquero F., Blázquez J. The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants. Mol. Microbiol. 2002, 43:1641-1650.
21. Oliver A., Cantón R., Campo P., Baquero F., Blázquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000, 288:1251-1254.
22. Overdevest I.T., Willemsen I., Elberts S., Verhulst C., Rijnsburger M., et al. Evaluation of the DiversiLab typing method in a multicenter study assessing horizontal spread of highly resistant gram-negative rods. J. Clin. Microbiol. 2011, 49:3551-3554.
23. Prunier A.L., Malbruny B., Laurans M., Brouard J., Duhamel J.F., et al. High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains. J. Infect. Dis. 2003, 187:1709-1716.
24. Román F., Cantón R., Pérez-Vázquez M., Baquero F., Campos J. Dynamics of long-term colonization of respiratory tract by Haemophilus influenzae in cystic fibrosis patients shows a marked increase in hypermutable strains. J. Clin. Microbiol. 2004, 42:1450-1459.
25. Rowe S.M., Miller S., Sorscher E.J. Cystic fibrosis. N. Engl. J. Med. 2005, 352:1992-2001.
26. Sievers F., Wilm A., Dineen D.G., Gibson T.J., Karplus K., et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol. 2011, 539.
27. Taddei F., Radman M., Maynard-Smith J., Toupance B., Gouyon P.H., et al. Role of mutator alleles in adaptive evolution. Nature 1997, 387:700-702.
28. Tenaillon O., Toupance B., Le Nagard H., Taddei F., Godelle B. Mutators, population size, adaptive landscape and the adaptation of asexual populations of bacteria. Genetics 1999, 152:485-493.
29. Turrientes M.C., Baquero M.R., Sánchez M.B., Valdezate S., Escudero E., et al. Polymorphic mutation frequencies of clinical and environmental Stenotrophomonas maltophilia populations. Appl. Environ. Microbiol. 2010, 76:1746-1758.
30. Valdezate S., Vindel A., Maiz L., Baquero F., Escobar H., et al. Persistence and variability of Stenotrophomonas maltophilia in cystic fibrosis patients, Madrid 1991-1998. Emerg. Infect. Dis. 2001, 1:113-122.
31. de Vrankrijker A.M., Wolfs T.F., van der Ent C.K. Challenging and emerging pathogens in cystic fibrosis. Paediatr. Respir. Rev. 2010, 11:246-254.
32. Waters V., Atenafu E.G., Lu A., Yau Y., Tullis E., et al. Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients. J. Cyst. Fibros. 2013, (January). pii:S1569-1993(12)00239-1.
33. Waters V., Yau Y., Prasad S., Lu A., Atenafu E., et al. Stenotrophomonas maltophilia in cystic fibrosis: serologic response on effect on lung disease. Am. J. Respir. Crit. Care Med. 2011, 183:635-640.